Preeclampsia Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Consumables, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Others), By Region and Competition, 2019-2029F

Global Preeclampsia Diagnostics Market was valued at USD 765.42 Million in 2023 and is expected to reach USD 958.53 Million by 2029 with a CAGR of 4.02% during the forecast period. The global preeclampsia diagnostics market is poised for significant growth as the medical community increasingly prioritizes the early detection and management of preeclampsia. Preeclampsia, a potentially severe pregnancy complication characterized by high blood pressure and damage to organs, affects approximately 5-8% of pregnant women worldwide. Early and accurate diagnosis is critical for improving maternal and fetal outcomes, driving the demand for advanced diagnostic solutions.

Preeclampsia diagnostics encompass a range of tests and technologies designed to detect the condition early and monitor its progression. Common diagnostic methods include blood pressure measurements, urine tests for proteinuria, and laboratory tests to assess liver and kidney function. Innovations in diagnostic tools, such as biomarker assays and novel imaging techniques, are enhancing the accuracy and efficiency of preeclampsia detection.

Increased awareness and focus on maternal and fetal health are driving the growth of the preeclampsia diagnostics market. Healthcare providers are placing greater emphasis on preventive care and early intervention to reduce the risks associated with preeclampsia. This shift in focus is leading to greater investments in diagnostic research, improved screening protocols, and more comprehensive patient management strategies.

Despite the positive outlook, the preeclampsia diagnostics market faces challenges such as high costs of advanced diagnostic technologies and variations in diagnostic practices across regions. However, these challenges present opportunities for innovation and market expansion. The development of cost-effective diagnostic solutions and the standardization of diagnostic protocols can address these challenges and enhance market growth.

Key Market Drivers

Rising Incidence of Preeclampsia

The primary driver of the preeclampsia diagnostics market is the critical need for early detection and intervention. Preeclampsia often develops after the 20th week of pregnancy and can escalate rapidly, leading to severe complications such as eclampsia, organ failure, and premature birth. Early diagnosis allows for timely management strategies, including medication and lifestyle adjustments, which can significantly improve maternal and fetal outcomes. As awareness of the benefits of early detection grows, so does the demand for advanced diagnostic solutions.

According to the World Health Organization (WHO), preeclampsia occurs in 2% to 10% of pregnancies globally. The incidence is higher in developing countries, ranging from 1.8% to 16.7%, compared to 0.4% in developed nations. In Pakistan, a developing country, preeclampsia rates are notably high, reaching up to 5% among pregnant women.

Technological advancements in diagnostic tools are playing a crucial role in addressing the rising incidence of preeclampsia. Innovations such as biomarker assays and advanced imaging techniques are enhancing the accuracy and efficiency of preeclampsia diagnosis. For instance, tests measuring biomarkers like soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are providing valuable insights into the likelihood of preeclampsia before clinical symptoms appear. Moreover, the integration of point-of-care testing devices and wearable technology is enabling real-time monitoring of blood pressure and other vital parameters, further driving market growth.

The growing emphasis on maternal health and preventive care is another significant factor driving the preeclampsia diagnostics market. Healthcare providers and policymakers are increasingly prioritizing the early detection and management of pregnancy-related complications. This focus has led to the development of comprehensive screening programs and improved diagnostic protocols, increasing the demand for advanced diagnostic solutions. Initiatives such as national screening programs and public health campaigns are raising awareness about the importance of early preeclampsia detection, contributing to market expansion.

A supportive regulatory environment is facilitating the growth of the preeclampsia diagnostics market. Regulatory agencies worldwide are working to streamline the approval and adoption of new diagnostic technologies. For example, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are providing clear guidelines and accelerated pathways for the approval of innovative diagnostic tools. This regulatory support encourages investment in research and development and accelerates the availability of new diagnostic solutions.

While the rising incidence of preeclampsia presents substantial opportunities for market growth, it also poses challenges. The high cost of advanced diagnostic technologies and variations in diagnostic practices across different regions can hinder market expansion. However, these challenges also offer opportunities for innovation. Developing cost-effective diagnostic solutions and standardizing diagnostic protocols can address these issues and enhance market growth.

Advancements in Maternal Health Monitoring

Recent advancements in maternal health monitoring technologies are significantly impacting the preeclampsia diagnostics market. High-resolution monitoring devices, such as continuous blood pressure monitors and advanced wearable sensors, provide real-time data on key physiological parameters. These technologies enable healthcare providers to track changes in blood pressure and other vital signs with greater precision. The continuous collection of data allows for early detection of anomalies that may indicate the onset of preeclampsia, facilitating timely intervention and management.

The development of wearable devices for monitoring maternal health is a major driver in the preeclampsia diagnostics market. These devices, which include smartwatches and fitness trackers equipped with sensors, monitor various health metrics such as blood pressure, heart rate, and activity levels. Remote monitoring technologies enable patients to track their health data from home and share it with healthcare providers in real-time. This accessibility enhances the ability to detect early signs of preeclampsia and provides a convenient way for expectant mothers to manage their health proactively.

In response to the FIGO (International Federation of Gynecology & Obstetrics) recommendations to extend preconception care through to the postpartum stage, the International Journal of Gynecology & Obstetrics introduced a new care model, PregCare, in 2023. This model is grounded in a holistic and multidisciplinary approach to maternal and fetal medicine for low-risk pregnancies. PregCare aims to modernize the traditional care model by reducing the frequency of in-office visits and enhancing virtual connectivity, point-of-care services, and self-care options. The model will be supported by an advanced PregCare call center, which integrates innovative technologies with a team of experienced perinatal professionals, including doctors, nurses, and midwives.

Artificial intelligence (AI) is increasingly being integrated into maternal health monitoring systems, offering advanced capabilities for analyzing complex health data. AI algorithms can process large volumes of data from various monitoring devices to identify patterns and predict the risk of preeclampsia. Machine learning models analyze historical and real-time data to provide predictive insights, enabling early diagnosis and personalized care. The use of AI in maternal health monitoring enhances diagnostic accuracy and supports proactive management of preeclampsia.

Advancements in maternal health monitoring are closely linked to the broader trend towards preventive healthcare in prenatal care. Continuous monitoring of vital signs and the use of advanced diagnostic tools allow for early identification of risk factors associated with preeclampsia. This focus on preventive measures helps in managing and mitigating the risks associated with preeclampsia, improving overall maternal and fetal health. The emphasis on early detection and preventive care is driving the adoption of advanced monitoring technologies and diagnostic solutions.

The development of comprehensive maternal health monitoring solutions that integrate various diagnostic tools and technologies is a significant driver of the preeclampsia diagnostics market. These solutions combine data from blood pressure monitors, wearable devices, and laboratory tests to provide a holistic view of maternal health. By integrating multiple sources of data, healthcare providers can gain a more accurate and complete understanding of a patient’s condition, leading to better diagnostic and treatment outcomes.

The rise of telemedicine and remote healthcare services is also contributing to the growth of the preeclampsia diagnostics market. Telemedicine platforms enable remote consultations and monitoring, allowing healthcare providers to track patient health data and provide timely guidance without requiring in-person visits. This expansion of telemedicine services enhances access to maternal health monitoring and diagnostic services, particularly in remote or underserved areas.

Advancements in maternal health monitoring also contribute to improved patient engagement and education. Modern monitoring devices often come with user-friendly interfaces and educational resources that empower expectant mothers to actively participate in their health management. Increased patient awareness and involvement in monitoring their health contribute to early detection of preeclampsia and better adherence to preventive measures.

Download Free Sample Report

Key Market Challenges

High Costs of Diagnostic Tests

Preeclampsia, a pregnancy complication characterized by high blood pressure and organ dysfunction, can be difficult to diagnose without proper awareness and education. Limited awareness among healthcare providers and expectant mothers about the early signs and risk factors of preeclampsia can result in delayed diagnosis and treatment. Educational initiatives are essential but often inadequate, particularly in low-resource settings.

The diagnosis of preeclampsia involves monitoring various clinical parameters, including blood pressure, protein levels in urine, and symptoms such as swelling and headaches. The complexity and variability of these indicators can complicate the diagnostic process. Additionally, some diagnostic tests may have limitations in sensitivity and specificity, leading to potential misdiagnoses or missed cases.

Advanced diagnostic tests for preeclampsia, such as biomarkers and specialized imaging, can be expensive. High costs associated with these tests can limit accessibility for patients in low- and middle-income countries, where healthcare resources may be constrained. This economic barrier can hinder early detection and timely management of the condition.

In many regions, particularly in underserved or rural areas, there is a lack of access to advanced diagnostic tools and technologies. Limited availability of high-quality diagnostic equipment and tests can result in delayed or inadequate screening for preeclampsia. Ensuring the distribution of advanced diagnostic tools across different healthcare settings remains a challenge.

There is variability in clinical guidelines and practices for the diagnosis and management of preeclampsia across different regions and healthcare systems. This lack of standardization can lead to inconsistent diagnostic practices and treatment protocols, affecting the overall effectiveness of preeclampsia diagnostics.

Integrating diagnostic data from various sources, such as blood tests, urine tests, and patient symptoms, can be challenging. Effective integration requires sophisticated data management systems and protocols to ensure that all relevant information is accurately considered in the diagnostic process. Inefficient data integration can lead to suboptimal diagnostic outcomes.

The development and validation of biomarkers for preeclampsia diagnosis face several challenges. Biomarkers must be highly specific and sensitive to differentiate preeclampsia from other conditions with similar symptoms. Research and development in this area are ongoing, but the process is complex and time-consuming, potentially delaying the availability of new diagnostic tools.

Healthcare systems in some regions may lack the infrastructure and resources required to implement comprehensive preeclampsia screening programs. Constraints such as limited staffing, inadequate training, and insufficient funding can impact the effectiveness of preeclampsia diagnostics and management.

Key Market Trends

Increased Focus on Early Detection

Advances in research are focusing on the identification of specific biomarkers associated with preeclampsia, such as soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and others. These biomarkers can indicate abnormal placental function and endothelial stress, allowing for earlier and more precise diagnosis. The use of biomarker panels and assays is becoming increasingly common, providing clinicians with valuable tools to predict and diagnose preeclampsia before symptoms become severe.

Point-of-care (POC) testing devices are designed for rapid, on-site diagnostic testing, which is crucial for managing preeclampsia. Innovations in POC technology enable real-time monitoring of key parameters such as blood pressure and proteinuria, reducing the need for laboratory-based testing and facilitating immediate clinical decisions. Portable devices and home testing kits are enhancing patient convenience and ensuring more frequent monitoring.

Imaging technologies, including Doppler ultrasound and 3D imaging, are improving the evaluation of uterine blood flow and placental health. Doppler ultrasound measures the velocity of blood flow in the uterine arteries, helping to assess the risk of preeclampsia. 3D and 4D imaging provide detailed views of the placenta and fetal development, aiding in the detection of anomalies that could indicate preeclampsia.

The emphasis on early screening is driven by the need to identify preeclampsia before it progresses to severe stages. Risk assessment tools and protocols are being developed to screen high-risk pregnant women more effectively. Routine screening for biomarkers and integrating risk prediction models into prenatal care are becoming standard practices.

Sophisticated risk prediction models are being developed that incorporate various clinical, biochemical, and demographic factors to estimate the likelihood of preeclampsia. These models use algorithms and machine learning techniques to analyze data from multiple sources, providing a more comprehensive risk assessment and facilitating early intervention.

There is a concerted effort to raise awareness about preeclampsia among healthcare professionals and the general public. Educational campaigns are focused on highlighting the symptoms, risk factors, and importance of early diagnosis. Training programs for healthcare providers are being implemented to improve their ability to recognize and manage preeclampsia.

Patient education initiatives are informing pregnant women about the signs of preeclampsia and the importance of regular prenatal check-ups. Enhanced patient education helps in early detection and encourages proactive health management, contributing to better outcomes.

Segmental Insights

Product Insights

Based on Product, Consumables have emerged as the fastest growing segment in the Global Preeclampsia Diagnostics Market in 2023. One of the primary reasons for the rapid growth of the consumables segment is the continuous innovation in diagnostic technologies. Consumables in preeclampsia diagnostics typically include test kits, reagents, and other disposable components used in assays and diagnostic procedures. Recent advancements in these technologies have led to more accurate and reliable tests for early detection of preeclampsia. For example, the development of new biomarker assays has enhanced the ability to measure critical indicators such as soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF). These innovations are driving demand for consumables, as healthcare providers seek the latest tools to improve diagnostic accuracy and patient outcomes.

Growing awareness about the importance of early detection and management of preeclampsia is also contributing to the rise in consumables. Public health campaigns and educational initiatives have emphasized the need for regular screening and early intervention to mitigate the risks associated with preeclampsia. As a result, there is a heightened focus on ensuring that diagnostic facilities are equipped with the necessary consumables to conduct these screenings effectively. The increasing adoption of routine screening practices in both developed and developing regions drives up the demand for consumable products.

Consumables are often more cost-effective compared to high-capital equipment and advanced diagnostic systems. This cost advantage makes them attractive to a wide range of healthcare settings, from large hospitals to smaller clinics and point-of-care facilities. The relatively lower cost of consumables compared to capital-intensive diagnostic machines facilitates broader adoption and use, particularly in regions with limited healthcare budgets. As healthcare systems strive to provide affordable and accessible diagnostic solutions, consumables play a crucial role in meeting these demands.

The rise of point-of-care (POC) testing has significantly impacted the consumables segment. POC testing allows for immediate diagnostic results at or near the site of patient care, which is essential for timely management of preeclampsia. Consumables used in POC tests, such as rapid diagnostic test kits and disposable testing devices, are in high demand as healthcare providers seek to improve patient throughput and diagnostic efficiency. The convenience and speed of POC testing are driving increased usage of these consumables.

The expansion of healthcare infrastructure, particularly in emerging markets, is another factor fueling the growth of consumables. As healthcare facilities are established or upgraded, there is a growing need for consumables to equip these new or enhanced diagnostic services. Investments in maternal health and diagnostics in developing regions are driving the procurement of consumables to support screening and monitoring of preeclampsia. This expansion supports the global growth of the consumables segment in the preeclampsia diagnostics market.

End User Insights

Based on End User, Hospitals have emerged as the dominating segment in the Global Preeclampsia Diagnostics Market during the forecast period. Hospitals possess the comprehensive infrastructure necessary to perform a wide range of diagnostic tests and procedures. They are equipped with state-of-the-art laboratories, advanced imaging technologies, and specialized equipment that are essential for the accurate diagnosis of preeclampsia. This infrastructure enables hospitals to offer a one-stop solution for expectant mothers, providing timely and precise diagnostics that are crucial for effective management of the condition.

Hospitals have access to a multidisciplinary team of healthcare professionals, including obstetricians, gynecologists, maternal-fetal medicine specialists, and diagnostic technicians. This specialized expertise is vital for the accurate diagnosis and management of preeclampsia. The collaborative approach in hospitals ensures that expectant mothers receive comprehensive care, from initial screening and diagnosis to ongoing monitoring and treatment, thereby improving patient outcomes.

Hospitals are at the forefront of adopting and implementing advanced diagnostic technologies. They utilize high-resolution ultrasound machines, continuous blood pressure monitors, and sophisticated laboratory tests to detect biomarkers associated with preeclampsia. These advanced technologies enhance the accuracy and reliability of preeclampsia diagnostics, enabling early detection and timely intervention. The ability to leverage cutting-edge diagnostic tools positions hospitals as leaders in the preeclampsia diagnostics market.

Hospitals offer integrated care services that go beyond diagnostics to include treatment and management of preeclampsia. They provide a continuum of care that encompasses prenatal visits, diagnostic screenings, monitoring, and emergency interventions if necessary. This integrated approach ensures that expectant mothers receive holistic care, addressing all aspects of their health and well-being. The comprehensive nature of hospital services makes them a preferred choice for expectant mothers seeking reliable and thorough preeclampsia diagnostics and care.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Preeclampsia Diagnostics Market in 2023. North America boasts a highly developed healthcare infrastructure that supports advanced diagnostic capabilities. The region's hospitals and diagnostic centers are equipped with state-of-the-art technologies for the detection and management of preeclampsia. This includes sophisticated imaging systems, biomarkers, and laboratory tests that are critical for accurate diagnosis and monitoring. The availability of such advanced infrastructure ensures that North American healthcare facilities can offer high-quality diagnostic services, reinforcing the region's leading role in the market.

Substantial investments in research and development (R&D) have played a crucial role in North America's dominance in the preeclampsia diagnostics market. The region is home to leading research institutions and universities that focus on advancing diagnostic technologies and developing new biomarkers for preeclampsia. These investments facilitate the continuous innovation and improvement of diagnostic tools, enabling more accurate and early detection of preeclampsia and contributing to North America's market leadership.

North American healthcare systems, particularly in the United States and Canada, are characterized by comprehensive healthcare policies that promote early diagnosis and management of conditions like preeclampsia. Policies such as routine prenatal screenings and preventive care guidelines ensure that pregnant women receive regular monitoring and timely diagnostics. Additionally, reimbursement policies and insurance coverage for diagnostic tests help to make preeclampsia diagnostics more accessible to a broader population, supporting the region's dominant position in the market.

There is a high level of awareness and education regarding preeclampsia in North America. Public health campaigns, educational programs, and professional training initiatives emphasize the importance of early detection and management of preeclampsia. This heightened awareness leads to increased demand for diagnostic services and promotes proactive healthcare practices. The availability of educational resources and training for healthcare professionals ensures that they are well-equipped to identify and manage preeclampsia, contributing to North America's leadership in the market.

Recent Development

• In January 2024, Labcorp launched a new test for assessing the risk and prognosis of severe preeclampsia in pregnant women. The BRAHMS sFlt-1/PlGF KRYPTOR Test System, available through physicians, is the first FDA-cleared biomarker test designed to aid in the risk assessment of progression to severe preeclampsia, a leading cause of maternal and fetal mortality in the U.S. Developed by Thermo Fisher Scientific, this test measures two angiogenic biomarkers associated with preeclampsia, serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), and was named one of TIME Magazine's Best Inventions of 2023.
• In February 2024, the Foundation for the National Institutes of Health (FNIH) announced a new public-private partnership aimed at developing tools to identify pregnant women at high risk of early-onset preeclampsia. This initiative, part of the FNIH Biomarkers Consortium, involves collaboration with the National Institutes of Health (NIH) and eight other partners, including life sciences companies, academia, and nonprofit and patient advocacy organizations.
• In May 2023, CSEM’s Tools for Life Sciences team partnered with MOMM Diagnostics to develop a cutting-edge point-of-care solution for preeclampsia diagnostics. This innovative multiplexed sensing device simultaneously detects two crucial biomarkers associated with preeclampsia using enzyme-linked lateral flow immunoassays (ELLFIA) with ion-sensitive electrodes in a disposable test cartridge. Accompanying the disposable test is a specialized digital readout device. This integrated approach provides a point-of-care diagnostic test platform that is 50 to 100 times more sensitive than traditional lateral flow immunoassays. MOMM Diagnostics’ comprehensive solution for rapid and reliable blood testing has significant potential to revolutionize clinical settings.

Key Market Players

• Diabetomics Inc.
• DRG INSTRUMENTS GMBH
• F. Hoffmann-La Roche Ltd
• Afekta Technologies Ltd.
• MOMM Diagnostics GmbH
• PerkinElmer Inc.
• Sera Prognostics, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Preeclampsia Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Preeclampsia Diagnostics Market, By Product:

o Instruments

o Consumables

o Others

• Preeclampsia Diagnostics Market, By End User:

o Hospitals

o Specialty Clinics

o Diagnostic Centers

o Others

• Preeclampsia Diagnostics Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preeclampsia Diagnostics Market.

Available Customizations:

Global Preeclampsia Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Preeclampsia Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]